

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Shanghai Haohai Biological Technology Co., Ltd.\***

**上海昊海生物科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6826)**

### **POSITIVE PROFIT ALERT**

This announcement is published by Shanghai Haohai Biological Technology Co., Ltd.\* (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to the Inside Information Provisions under of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. This announcement is also published on the website of the Shanghai Stock Exchange simultaneously.

The board of directors of the Company (the “**Board**”) hereby informs the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company that, based on the information currently available to the Group and its preliminary assessment of the unaudited consolidated management accounts of the Group for the nine months ended 30 September 2021 (the “**Reporting Period**”), the Group is expected to record an unaudited net profit attributable to shareholders of the Company of approximately RMB300,000,000 to RMB330,000,000 during the Reporting Period, representing an increase of approximately RMB187,353,100 to RMB217,353,100, or approximately 166.32% to 192.95%, as compared to that in 2020 (corresponding period in 2020: an unaudited net profit attributable to shareholders of the Company of RMB112,646,895.39). The unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB280,000,000 to RMB310,000,000, representing an increase of approximately RMB187,985,800 to RMB217,985,800, or approximately 204.30% to 236.90%, as compared to that in 2020 (corresponding period in 2020: unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss of RMB92,014,160.78).

As far as the Board is aware, the profit growth for the Reporting Period as compared to the corresponding period in 2020 was mainly due to the significant impact of the COVID-19 pandemic (the “**Pandemic**”) on the sales of the Group’s major products in the corresponding period in 2020, and the recovery of the economy in China and the recovery and growth in domestic market demand for the Group’s main products as a result of the effective control of the Pandemic during the Reporting Period as compared to the corresponding period in 2020 although the impact of the Pandemic still exists. Meanwhile, the Group grasped the favorable market, scientifically organized production and operation and carried out all kinds of sales and marketing activities to expand brand awareness and influence, and made the sales of the Group’s products, especially new products, had a large increase during the Reporting Period compared with the corresponding period in 2020.

The Board hereby reminds the Shareholders and potential investors of the Company that the information set out in this announcement is based on an assessment with reference to the information currently available to the Group and has not been reviewed by the audit committee of the Company and the independent auditors. The Group is still finalizing the unaudited results for the nine months ended 30 September 2021 (the “**Third Quarterly Report**”), which are subject to adjustments (if necessary). The Third Quarterly Report may differ from the data set out in this announcement. Shareholders and potential investors of the Company are advised to read carefully the details of the Group’s Third Quarterly Report, which is expected to be published in late October 2021.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Shanghai Haohai Biological Technology Co., Ltd.\***  
*Chairman*  
**Hou Yongtai**

Shanghai, the PRC, 15 October 2021

*As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Huang Ming; and the independent non-executive directors of the Company are Ms. Li Yingqi, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe and Mr. Zhao Lei.*

\* *For identification purpose only*